Mydriasis Treatment, Companies, Market Trends

Mydriasis is the pupil's dilation, which may be due to a non-physiological cause such as disease, trauma, drug usage, or physiological pupillary response. A mydriatic is an agent, which induces dilation of the pupil; it is routinely used to help examination of the retina and other deep eye structures. In general medical practice, pupil dilation's most frequent indication is in the screening of diabetic retinopathy followed by macular degeneration.

This condition can be a symptom of an injury to the brain from physical trauma or a stroke and can affect one pupil at a time or both. The pupillary dilation pathway is controlled by the iris dilator muscle that consists of fibers that are oriented radially and connect the iris's exterior with the interior. When the dilator muscle contracts, it pulls the iris's interior outward, thus increasing the pupil's size. Moreover, the iris dilator muscle is controlled by the sympathetic nervous system, the part of the autonomic nervous system involved in arousal, wakefulness, and the fight or flight response.

Mydriasis Epidemiological Segmentation

The Epidemiological Segmentation of Mydriasis in 7MM from 2017 to 2030 is segmented as:-

Total Prevalent cases of Mydriasis
Gender-Specific cases of Mydriasis
Age-Specific cases of Mydriasis
Total Diagnosed and Treatable cases of Mydriasis

Mydriasis Epidemiology

The diagnosed prevalent population of Mydriasis in the United States in 2017 was 3,580,350
There were 1,390,000 Cataract Surgeries performed in age-specific cases (70–79) in the United States in 2017

Mydriasis Market

The market size of Mydriasis in 7MM in 2017 was USD 104.52 million

Mydriasis Market Drivers